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Introduction {#sec1}
============

The generation of high-affinity antibodies requires naive CD4^+^ T cells to sequentially be activated, proliferate and differentiate, acquire proximity to the B cell follicles, and provide B cells with "help" in the form of antigen-specific interactions, co-receptor binding, and cytokine signaling. These specialized CD4 cells have been termed T follicular helper (Tfh) cells, and they are essential to promote the germinal center (GC) reaction including B cell expansion, class switching, selection, and development of high-affinity antibody-forming cells ([@bib25; @bib8; @bib48]). In the past several years, much has been learned about Tfh cell differentiation; however, the cellular programming leading to this state remains incompletely understood.

Inducible T cell co-stimulator (ICOS) is a potent co-receptor distinct from CD28 that is induced on activated T cells and highly expressed on Tfh cells. ICOS signaling is necessary for complete GC development, T cell-dependent B cell help, and antibody class switching ([@bib49]), and this is due to a role for ICOS in the differentiation of activated T cells to Tfh cells ([@bib48]).

Tfh cell differentiation is a multi-step process that begins with dendritic cell priming and further requires B cells for additional differentiation and maintenance ([@bib8; @bib48]). The initial dendritic cell priming is sufficient to induce a CXCR5^+^BCL6^+^ Tfh cell, and this was found to be dependent on ICOS signaling ([@bib38]). However, further ICOSL stimulation from B cells is required for the final differentiation and maintenance of GC-Tfh cells ([@bib36; @bib8]), and this is consistent with studies showing that ICOS is able to influence homing to GCs through the induction of filopodia ([@bib13; @bib53]). Signal transduction through ICOS results in the potent activation of phosphoinositide-3 kinase (PI3K), and this is a key event in Tfh differentiation ([@bib41]). In a manner not yet understood, this leads to increased expression of BCL6, which has been described as an essential transcription factor for the differentiation and function of Tfh cells ([@bib6]).

A major pathway downstream of PI3K signaling is the AKT-mediated inactivation of FOXO family transcription factors. AKT mediates the triple phosphorylation of FOXO proteins causing their nuclear egress ([@bib4]). FOXO transcription factors are important for the expression of cyclin-dependent kinase inhibitors and proapoptotic molecules, and thus their inhibition is an essential aspect of growth factor-mediated cell-cycle progression and survival. In T cells, FOXO transcription factors have been shown to regulate multiple, specialized functions including the expression of the *Il7ra* and *Klf2*---control points for T cell survival and homing ([@bib32; @bib18]). In addition, mice with a T cell-specific deletion of *Foxo1* lack functional FOXP3^+^ Treg cells and spontaneously develop systemic autoimmunity. We previously noted that these mice accumulate a large population of Tfh cells, form GCs, and produce circulating, anti-DNA antibodies, and we proposed that the PI3K-AKT-FOXO1 signaling pathway controls lineage commitment that, in part, specifies the Treg versus Tfh alternative cell fates ([@bib22; @bib18]). Though provocative, these experiments highlight a necessity to study the role of FOXO transcription factors in T cell differentiation without the complications of autoimmunity caused by an insufficiency of Treg cells. In support of this idea, a report recently appeared showing that the ubiquitin ligase, ITCH, facilitates Tfh differentiation, and indeed it appears to act through the degradation of FOXO1 ([@bib52]). Here, we test the proposition that ICOS signaling acts to initiate a program of Tfh differentiation through inhibition of FOXO1 and the resulting effects on gene expression. Specifically, the deletion of *Foxo1* results in enhanced BCL6 expression and exaggerated differentiation of Tfh cells.

Results {#sec2}
=======

Loss of FOXO1 Amplifies Tfh Differentiation {#sec2.1}
-------------------------------------------

In accord with the high prevalence of Tfh cells in mice with a T cell-specific *Foxo1* deletion ([@bib22]), we tested whether ICOS-mediated FOXO1 inactivation constitutes an important step in Tfh cell differentiation. As such, we adoptively transferred *Foxo1*^f/f^*Cd4Cre*^+^CD45.2^+^ (*Foxo1*^TKO^) OTII or *Foxo1*^f/f^CD45.2^+^ (wild type, WT) OTII cells into CD45.1 mice. In this and subsequent experiments, the starting population was depleted of CD25^+^CD69^+^ cells prior to transfer. Host mice were then immunized with OVA plus adjuvant. Four days post-immunization WT and *Foxo1*^TKO^ OTII cells were fully activated as determined by CD44 expression (data not shown), and the WT OTII cells differentiated into three cell populations: CXCR5^lo^BCL6^lo^ cells, described as T effector (Teff) cells; CXCR5^int^ cells, Tfh cells; and CXCR5^hi^BCL6^hi^ T cells that are destined to be GC-Tfh cells ([@bib36; @bib25]). By contrast, almost all *Foxo1*^TKO^ OTII cells displayed CXCR5^int^ expression characteristic of Tfh cells ([Figure 1](#fig1){ref-type="fig"}A). Consistent with this, PD1 expression was also elevated in *Foxo1*^TKO^ compared to WT T cells ([Figure 1](#fig1){ref-type="fig"}A).

Contrary to expectations given the role of FOXO transcription factors in the expression of Bim and Fas-ligand ([@bib4; @bib14]), there was a decrease in the total number of *Foxo1*^TKO^ T cells compared with WT ([Figure S1](#app2){ref-type="sec"}A). The analysis of cultured T cells showed that this defect in accumulation was not due to retarded cell division, but rather, increased apoptosis ([Figure S1](#app2){ref-type="sec"}B--1F). It is cell-intrinsic ([Figure S1](#app2){ref-type="sec"}D), and could be completely rescued by the addition of a pan-caspase inhibitor ([Figure S1](#app2){ref-type="sec"}F). Although activation via interleukin-2 (IL-2) or a superantigen leads to FOXO1 inactivation ([@bib46; @bib11]), an important point is that this inactivation was transient, such that at least by 24 hr post-activation, FOXO1 contributed to CD4^+^ T cell survival.

All three populations were reduced with a *Foxo1* deletion, although the decrease was minimal for Tfh (CXCR5^int^) cells ([Figure 1](#fig1){ref-type="fig"}B). IL-7 is required for naive T cell survival and normal expression of BCL2 in naive T cells, and it increases Tfh cell differentiation ([@bib47; @bib43]). As Foxo1-deficient naive cells have reduced expression of IL-7Rα ([@bib21]), we determined whether enforced expression of *Il7ra* ([@bib54]) would rescue survival or alter the course of the response. Results showed no effect of *Il7ra* expression on the proportion or number of *Foxo1*^TKO^ cells that became Tfh cells ([@bib22]; data not shown).

A *Foxo1* loss of function was further tested by acute deletion just prior to immunization. After treatment with tamoxifen, T cells were harvested from *Foxo1*^f/f^ *Rosa26*^Cre-ERT2^ OTII (*Foxo1*^KO^) and *Rosa26*^Cre-ERT2^ OTII mice (WT) ([@bib21]) and transferred into naive hosts. The starting and unimmunized OTII populations from these mice were equivalent for the expression of CD44 and CXCR5 ([Figure S1](#app2){ref-type="sec"}G and data not shown). Notably, the proportion of *Foxo1*^KO^ OTII cells that acquired a CD44^hi^ activated phenotype day 4 post immunization was equivalent to WT, and yet similar to *Foxo1*^TKO^ T cells, nearly all *Foxo1*^KO^ OTII cells displayed a CXCR5^int^ phenotype ([Figures 1](#fig1){ref-type="fig"}C and [S1](#app2){ref-type="sec"}G). Similar to *Foxo1*^TKO^ T cells, further analysis of this CXCR5^int^ Tfh subset revealed higher expression of CXCR5, BCL6, and PD1 in *Foxo1*^KO^ cells compared with the equivalent WT CXCR5^int^ population ([Figures 1](#fig1){ref-type="fig"}D and [S1](#app2){ref-type="sec"}H).

To determine whether these effects applied to other immunization conditions, we analyzed the response to infection with *Listeria monocytogenes*. After adoptive transfer of OTII cells, host mice were infected with *actA*-deficient *Listeria monocytogenes* (ΔActA-Lm) expressing OVA ([@bib9]), and the analysis day 4 post infection revealed that virtually all the *Foxo1*^KO^ OTII cells were CXCR5^+^ ([Figure 1](#fig1){ref-type="fig"}E). Again, within the CXCR5^+^ population, *Foxo1*^KO^ T cells were uniformly higher by approximately two-fold for the expression of CXCR5, BCL6, and PD1 ([Figure 1](#fig1){ref-type="fig"}E).

A defining characteristic of Tfh cells is location within the B cell follicles, whereas the eponymous GC-Tfh cells are located within GCs. To analyze the role of FOXO1 in localization, we determined the expression of homing molecules in addition to CXCR5. As expected, based on the control of *Klf2* by FOXO1 ([@bib12; @bib21]), virtually all *Foxo1*^KO^ OTII cells were CD62L^−^ 4 days post immunization, whereas the WT T cells displayed heterogeneous expression ([Figure 1](#fig1){ref-type="fig"}F). CCR7 expression was unchanged with respect to activated WT T cells, but a proportion of the *Foxo1*^KO^ OTII cells were low for PSGL1 ([Figure 1](#fig1){ref-type="fig"}F), a phenotype that allows T cells to exit the T cell zone ([@bib8]). Combined with the expression of CXCR5 (e.g., [Figure 1](#fig1){ref-type="fig"}D), *Foxo1*^KO^ OTII cells appear to express a repertoire of homing molecules that would promote homing to B cell areas of the spleen ([@bib8]).

WT or *Foxo1*^KO^ OTII T cells were directly examined 4 days after immunization by immunohistology. WT OTII cells were mostly found within the splenic T cell zone including some cells along the T cell-B cell border. In contrast, a larger proportion of the *Foxo1*^KO^ OTII cells was found in the follicle with relatively few cells found deep within the T cell zone ([Figure S1](#app2){ref-type="sec"}I). However, we note that the *Foxo1*^KO^ cells were also not found deep in the B cell follicle.

The Regulation FOXO1 and ICOS Is Coupled via a Negative Feedback Loop {#sec2.2}
---------------------------------------------------------------------

To analyze the relationship between ICOS signaling and FOXO1, we tested whether ICOS signaling would inactivate FOXO1 via nuclear egress ([@bib4]). Naive CD4^+^ T cells expressing a FOXO1-GFP fusion protein were activated for 48 hr under iTfh conditions, rested for 24 hr, and restimulated for 30 min with antibody specific for CD3 in the presence or absence of agonist ICOS-specific antibody. At 30 min post restimulation there was no difference in the amount of FOXO1-GFP in live cells ([Figure 2](#fig2){ref-type="fig"}A, left). However, upon restimulation through CD3 and ICOS, but not CD3 alone, the similarity score (ImageStream analysis) for DRAQ5 (nucleus) and FOXO1-GFP was reduced; this corresponds with reduced co-localization and nuclear FOXO1 ([Figure 2](#fig2){ref-type="fig"}A, middle). In agreement, there was an increased percentage of cells stimulated through ICOS that displayed FOXO1-GFP exclusively in the cytoplasm ([Figure 2](#fig2){ref-type="fig"}A, right). However, at 24 hr post restimulation through CD3 and ICOS, the amount of FOXO1-GFP was increased with little difference in the DRAQ5, FOXO1-GFP similarity score ([Figure 2](#fig2){ref-type="fig"}B, left, middle). Consistent with these results, nuclear intensity of FOXO1-GFP was not diminished in live cells 24 hr post-restimulation through CD3 and ICOS ([Figure 2](#fig2){ref-type="fig"}B, right). These observations show nuclear FOXO1, which was lost at 30 mim post-activation, was reestablished by 24 hr.

FOXO transcription factors have been shown to positively regulate the transcription of growth factor receptors (e. g., IL-7Rα, insulin receptor) that, in turn, signal through PI3K to cause FOXO inactivation ([@bib17; @bib21]). This creates a negative feedback loop. Activation through CD3 and CD28 induced ICOS expression in WT T cells, and this induction was attenuated in *Foxo1*^KO^ T cells ([Figure 2](#fig2){ref-type="fig"}C, left). Because ICOS signaling also inactivated FOXO1, how is ICOS maintained in differentiating Tfh cells? To examine this, we further measured ICOS expression in iTfh cultures and found that ICOS was superinduced in WT T cells consistent with the phenotype of Tfh cells, and its expression became relatively less FOXO1 dependent ([Figure 2](#fig2){ref-type="fig"}C, right). *Foxo1*^KO^ T cells cultured in iTfh conditions expressed an amount of ICOS at least equivalent to WT T cells co-stimulated through CD28. A conclusion is that although ICOS could be potentially subject to negative feedback regulation, there are two ways in which this is tempered. One, ICOS-mediated FOXO1 inactivation is transient ([Figures 2](#fig2){ref-type="fig"}A and 2B), and two, FOXO1 dependence is reduced under iTfh conditions ([Figure 2](#fig2){ref-type="fig"}C, right). In vivo activation also revealed ICOS induction compared with naive T cells, and its expression was progressively higher comparing Teff (CXCR5^lo^), Tfh cells (CXCR5^int^) and GC-Tfh (CXCR5^hi^BCL6^hi^) cells. In all three subsets, the ICOS induction was partially dependent upon FOXO1 ([Figure 2](#fig2){ref-type="fig"}D).

The results suggested the possibility that FOXO1 directly regulates *Icos* expression. To analyze FOXO1 chromosomal binding in naive T cells, we carried out a whole-genome scan for FOXO1 binding sites in CD4 T cells (ChIP-seq) ([@bib19]). Accuracy of the analysis was verified by an examination of the average tags per position, genomic GC content, and the distribution of peaks between regions of the genome ([Figure 2](#fig2){ref-type="fig"}E). The most frequent binding site corresponded with the known FOXO-DAF16 consensus site ([Figure 2](#fig2){ref-type="fig"}E) ([@bib18]). In addition, the analysis pinpointed binding sites in the *Il7r* and *Ctla4* genes we have previously identified as evolutionarily conserved and bound by FOXO1 ([@bib21; @bib22]) ([Figure S2](#app2){ref-type="sec"}A). These data further revealed that in CD4 T cells, FOXO1 is bound to an evolutionarily conserved FOXO consensus binding site in the *Icos* promoter ([Figures 2](#fig2){ref-type="fig"}F and [S2](#app2){ref-type="sec"}B) and remains bound after activation for 48 hr ([Figure 2](#fig2){ref-type="fig"}G). Thus, similar to *Il7ra* and *Ctla4*, *Icos* expression is dependent in part on FOXO1, and the *Icos* gene is bound by FOXO1 at an evolutionarily conserved promotor binding site.

Tfh Cell Differentiation in the Absence of FOXO1 Is Independent of ICOSL {#sec2.3}
------------------------------------------------------------------------

FOXO1-deficient T cells have diminished expression of ICOS, and yet exhibit enhanced Tfh differentiation. This, combined with the ICOS-dependent inactivation of FOXO1 suggested that genetic ablation of FOXO1 would promote ICOS-independent Tfh differentiation. To test this, we analyzed the dependence of Tfh differentiation on ICOSL in two ways. In one set of experiments, we transferred WT or *Foxo1*^KO^ T cells in the presence or absence of antibodies specific for ICOSL. In a second set of experiments, we transferred T cells into WT or *ICOSL*^−/−^ hosts. In these experiments, the results were similar. Although the presence of WT Tfh cells displayed a strong dependence on ICOSL recognition, this dependence was greatly reduced for *Foxo1*^KO^ T cells ([Figure 3](#fig3){ref-type="fig"}A--3D). Importantly, in both experimental models, the number of *Foxo1*^KO^ CXCR5^+^ OTII cells was substantially greater than the number of WT CXCR5^+^ cells under these conditions ([Figures 3](#fig3){ref-type="fig"}B and 3D). In particular, although the differentiation of WT cells was virtually lost in *Icosl*^−/−^ hosts ([Figures 3](#fig3){ref-type="fig"}C and 3D) ([@bib5; @bib36]), in the absence of FOXO1 the mean *number* of CXCR5^+^ T cells was increased by 10-fold over WT controls ([Figure 3](#fig3){ref-type="fig"}D). Further experiments showed that CXCR4 induction, shown to have a stringent requirement for ICOS in WT T cells ([@bib30]) was induced in *Foxo1*^KO^ T cells in an ICOS-independent manner ([Figures S3](#app2){ref-type="sec"}A and S3B). From these data, we conclude that loss of FOXO1 facilitates differentiation into Tfh cells with a greatly diminished requirement for ICOS signaling, i.e. FOXO1 inactivation is epistatic to ICOS expression and signaling.

Loss of FOXO1 Promotes B Cell Help and Anti-DNA Antibodies in the Absence of ICOS {#sec2.4}
---------------------------------------------------------------------------------

To determine whether loss of *Foxo1* could complement a loss of *Icos*, we bred *Foxo1*^TKO^ with *Icos*^−/−^ mice and analyzed the proportion of CXCR5^+^PD1^+^ cells from each of four genotypes. To account for the increase in activated CD4 cells in the *Foxo1*^TKO^ mice and the reduced population of activated cells in *Icos*^−/−^ mice ([@bib30; @bib22]), we focused on the activated CD4^+^ (CD44^hi^) population. In addition, we enumerated class-switched and GC B cells. For each of these parameters, the deficiencies displayed by *Icos*^−/−^ mice were all or partially rescued by the inclusion of the *Foxo1*^TKO^ alleles ([Figures 4](#fig4){ref-type="fig"}A--4C). Although little to no immunoglobulin G (IgG) isotype anti-DNA antibodies were detected in the *Icos*^−/−^ mice, significant titers were measured in DKO mice ([Figure 4](#fig4){ref-type="fig"}D, left). DKO mice also had significantly higher levels of total IgG levels in the sera than *Icos*^−/−^ mice ([Figure 4](#fig4){ref-type="fig"}D, right). The presence of GCs and isotype switched antibodies was not simply due to a lack of regulatory FOXP3^+^ Tfh (T~FR~) cells, beacuse the frequency of the CXCR5^+^ Tfr population within the Treg population was not reduced with the deletion of *Foxo1* ([Figure 4](#fig4){ref-type="fig"}E). These data indicate that deletion of *Foxo1* in T cells is sufficient to allow differentiation of a Tfh-like cell in the absence of ICOS, and these cells cooperate with B cells to produce isotype-switched, anti-DNA antibodies---at least in the absence of effective Treg cells.

FOXO1 Negatively Regulates BCL6 Expression {#sec2.5}
------------------------------------------

If the loss of FOXO1 is important for Tfh differentiation, then a prediction is that FOXO1 inhibition as a consequence of ICOS signaling will facilitate the induction of BCL6 expression ([@bib5]). In naive cells, the low amount of BCL6 detected was unchanged between WT and *Foxo1*^KO^ mice (data not shown). T cells were activated for 48 hr under iTfh conditions, and they were rested for 24 hr and re-stimulated with or without ICOS-specific antibody for a further 24 hr. Restimulation through ICOS increased BCL6 expression, whereas it was substantially higher in *Foxo1*^KO^ T cells compared with WT T cells under all conditions ([Figure 5](#fig5){ref-type="fig"}A). In particular, *Foxo1*^KO^ T cells re-stimulated through CD3 alone expressed more BCL6 than WT T cells stimulated through CD3 and ICOS. There was a further induction of BCL6 in the *Foxo1*^KO^ T cells stimulated through ICOS (compare anti-CD3 with anti-CD3 plus anti-ICOS), and this suggests that an additional pathway downstream of ICOS might play a role in BCL6 induction. Similar to protein expression, WT *Bcl6* RNA increased upon restimulation in the presence of anti-ICOS, and it was expressed in higher amounts in *Foxo1*^KO^ cells compared to WT cells ([Figure 5](#fig5){ref-type="fig"}B). Furthermore, this increase in BCL6 was cell-intrinsic ([Figure 5](#fig5){ref-type="fig"}C), and it was not secondary to selective death of *Foxo1*^KO^ T cells ([Figure S4](#app2){ref-type="sec"}A).

Analysis of FOXO1 binding by ChIP-Seq in naive CD4 T cells showed that FOXO1 is exclusively bound to the *Bcl6* locus at the boundary of the first (38 bp) non-coding exon and the first intron ([Figures 5](#fig5){ref-type="fig"}D and [S4](#app2){ref-type="sec"}B). This region includes tandem sequences separated by 30 bases that are very similar to the conserved FOXO1 consensus site ([Figures 5](#fig5){ref-type="fig"}D and [S4](#app2){ref-type="sec"}B), and we have also found this peak in naive and activated CD8 T cell data sets (data not shown). This region is highly conserved between mice and human beings and this conservation extends to a comparison of marsupials and eutherian mammals, implying evolutionary selection for at least 130 million years ([Figure S4](#app2){ref-type="sec"}C).

FOXO1 binding to this site in naive T cells was confirmed by ChIP analysis ([Figure 5](#fig5){ref-type="fig"}E). We further examined whether FOXO1 binding is lost under conditions of T cell stimulation. After 48 hr of iTfh activation, cells were rested for 24 hr and tested (None), or re-stimulated through CD3 and ICOS for 1 hr or 24 hr. As shown, FOXO1 was bound to this site in T cells activated under iTfh conditions, but it was reduced upon restimulation with through CD3 and ICOS ([Figure 5](#fig5){ref-type="fig"}F). This is consistent with the initially reduced nuclear localization of FOXO1 ([Figure 2](#fig2){ref-type="fig"}A). However, nuclear FOXO1 is not decreased 24 hr post-restimulation through CD3 and ICOS ([Figure 2](#fig2){ref-type="fig"}B), and yet binding of FOXO1 to *Bcl6* was still reduced ([Figure 5](#fig5){ref-type="fig"}F). These data are consistent with FOXO1 binding to the *Bcl6* gene and mediating transcriptional repression that is relieved upon ICOS signaling; however, we lack direct evidence for transcription repression that might include germline mutations in the tandem FOXO1 binding sites.

Further analysis of the 4333 FOXO1 genomic binding sites revealed many genes involved in Tfh differentiation located within close proximity. Inspection of *Cxcr5*, *Batf*, *Ccr7*, *Cxcr4*, *Irf4*, *Selplg* (P-selectin ligand-CD162), and *Maf* loci revealed one or more strong FOXO1 binding sites located near the transcriptional start site or within several kilobases ([Figure S5](#app2){ref-type="sec"}). The exception was *Maf*, which is functionally important for terminally differentiated GC-Tfh cells ([@bib25]).

Enforced Nuclear Localization of FOXO1 Prevents Tfh Differentiation {#sec2.6}
-------------------------------------------------------------------

If FOXO1 inactivation is required for Tfh differentiation, enforced nuclear localized would be predicted to block the appearance of Tfh cells. To test this, we transduced T cells from OTII *Foxo1*^AAA^ mice with a Hit and Run CRE recombinase retrovirus and adoptively transferred them ([@bib44; @bib34]). After immunization, *Foxo1*^AAA^ T cells expressed CD44^+^ (data not shown) and displayed superinduction of ICOS ([Figure 6](#fig6){ref-type="fig"}A) consistent with the importance of FOXO1 in the regulation of the *Icos* gene. Despite this, *Foxo1*^AAA^ T cells displayed a reduced ability to differentiate into the Tfh phenotype as compared to WT ([Figure 6](#fig6){ref-type="fig"}B). The accumulation of *Foxo1*^AAA^ T cells was also reduced (data not shown), and the origin of this defect is a topic of further investigation.

*Foxo1*^KO^ T Cells Have Reduced Ability to Differentiate into GC-Tfh Cells {#sec2.7}
---------------------------------------------------------------------------

To characterize the role of FOXO1 in GC-Tfh differentiation, we examined a polyclonal response to *L. monocytogenes*. For this, we generated mixed WT:*Foxo1*^TKO^ bone-marrow chimeras ([@bib22]). Mice were infected with ΔActA-Lm, and at day 9 the CXCR5^int^ (and total CXCR5^+^ cells) cells were overrepresented within the *Foxo1*^TKO^ population compared with WT cells. Surprisingly there was a notable paucity of *Foxo1*^TKO^ CXCR5^hi^BCL6^hi^ GC-Tfh cells ([Figure 7](#fig7){ref-type="fig"}A).

Studies have shown that MAF is an important transcription factor in Tfh development, and in particular, it might be essential for IL-4 expression associated with GC-Tfh cells ([@bib25; @bib8; @bib48]). Consistent with this, analysis of WT OTII T cells 4 days after activation in vivo revealed that only the CXCR5^hi^ PD1^hi^ subset expressed high amounts of MAF ([Figure 7](#fig7){ref-type="fig"}B), and this was abrogated by treatment of the mice with anti-ICOSL ([Figure 7](#fig7){ref-type="fig"}C). Compatible with the lack of a BCL6^hi^ population at GC time points, *Foxo1*^KO^ T cells were selectively deficient in the MAF^+^ population at both day 4 and day 7 post immunization ([Figure 7](#fig7){ref-type="fig"}D). In addition, *Foxo1*^KO^ OTII T cells did not give rise to CXCR5^hi^BCL6^hi^ or CXCR5^hi^PD1^hi^ cells day 7 post immunization ([Figure 7](#fig7){ref-type="fig"}E), and at this time, FOXO1 is consistently expressed ([Figure 7](#fig7){ref-type="fig"}F). Similar results were found following infection with VSV-OVA ([Figures 7](#fig7){ref-type="fig"}G and 7H). In sum, these data show that genetic inactivation of *Foxo1* exaggerates the differentiation of Tfh cells in an ICOS-independent manner, and yet, FOXO1 plays a role in the final differentiation to GC-Tfh cells.

Discussion {#sec3}
==========

Previous work established an early role for ICOS and and its activation of PI3K signaling in the differentiation of CD4 T cells into Tfh cells, and this signaling pathway influences the induction of key molecules including BCL6, MAF, IL-4, and IL-21 ([@bib1; @bib15; @bib40; @bib5]). Since the basis for PI3K regulation of cell growth and differentiation largely emanates through AKT-mediated inhibition of FOXO1 transcriptional activity ([@bib4]), we wished to test the idea that *Foxo1* is epistatic to *Icos* in the elaboration of one or more of these Tfh characteristics. Additionally, two recent papers suggest that reduced expression of FOXO1, either due to increased expression of ICOS induced by loss of FOXP1, or due to ITCH-mediated degradation, may increase Tfh differentiation ([@bib51; @bib52]). The studies described in this report provide a mechanism for those findings.

Tfh cells at the B-follicular border express CXCR5 and BCL6 ([@bib39]), whereas GC-Tfh cells can be characterized by MAF expression. Here we show that deletion of *Foxo1* exaggerated the initial antigen-driven step in Tfh differentiation resulting in an expanded proportion of CXCR5^+^ CD4 T cells localized to the border of B cell follicles. *Foxo1*^KO^ T cells were proportionately overrepresented as CXCR5^int^BCL6^int^ cells, and in addition these Tfh cells expressed amounts of CXCR5, BCL6, PD1, and CXCR4 greater than those of the equivalent WT Tfh populations---although not to the level characteristic of GC-Tfh cells. In fact, in the absence of FOXO1, despite the increased proportion of Tfh cells, few GC-Tfh cells emerged even as late as 9 day post ΔActA-Lm infection. Our conclusion is that a transient inactivation of FOXO1 skews the contingency of effector versus Tfh differentiation, whereas progression to mature GC-Tfh cells is promoted by FOXO1.

We emphasize that FOXO1 inactivation is only transient. In T cells stimulated through CD3 and ICOS, nuclear FOXO1-GFP is reduced at 30 min but reestablished within 24 hr. Moreover, FOXO1 is required for T cell viability as early as 24 hr post activation. Whether there are mechanisms opposing AKT signaling or desensitizing ICOS signaling is not known; however, stress kinase phosphorylations, glycosylation, or methylation have all been shown to encourage nuclear location of FOXO factors ([@bib18]). This is further illustrated by regulation of ICOS. Although FOXO1 clearly has a role for full ICOS expression, ICOS is induced early in DC-mediated antigen presentation, and remains high in Tfh and GC-Tfh cells despite its potential for signaling via PI3Kδ and causing negative feedback inactivation of FOXO1. Thus, although genetic ablations presented here and elsewhere point to an important contingency-based inactivation of FOXO1 ([@bib51; @bib52]), they do not recapitulate the dynamics of FOXO1 inactivation. Furthermore, FOXO1 appears to be required for GC-Tfh differentiation, although the mechanism of action is unknown. The reduced expression of ICOS might limit the ability of *Foxo1*^KO^ Tfh cells to generate filopodia, which allow for Tfh cells to home from the T-B border to the GC ([@bib53]). This possibility would be consistent with the presence of GC-Tfh cells in *Foxo1*^TKO^ mice contrasted with the loss of *Foxo1*^KO^ GC-Tfh cells in competition with WT cells. FOXO1 has also been shown to bind to the *Ifng* locus and inhibit expression of IFN-γ ([@bib34]), and thus in its absence, ectopic gene expression might subvert GC-Tfh differentiation. The most parsimonious explanation is that FOXO1 directly regulates the transcription of genes required for full GC-Tfh differentiation.

A complication described here is the observation that activated *Foxo1*^−/−^ CD4 T cells have a reduced viability compared to WT T cells. This raised the possibility that the increase in the proportion of Tfh cells could be due to selective death of Teff cells; however, the results show that this alone cannot explain the phenotype of *Foxo1*^−/−^ T cells. If the exaggerated proportion of Tfh cells were due only to preferential loss of Teff cells, then there would be no reduction in the requirement for ICOS signaling. In two different types of experiments we show that *Foxo1*^KO^ T cells differentiate into Tfh cells with a substantially reduced requirement for ICOS signaling. Similarly, the induced expression of BCL6 is an important part of the Tfh program, and loss of FOXO1 results in the increased expression of BCL6 compared to wild-type, even when apoptosis is blocked. In a separate line of experimentation, loss of *Foxo1* genetically complemented the loss of *Icos* in that there emerged CXCR5^+^PD1^+^ cells, GC-B cells and anti-DNA IgG antibodies. In addition, a role for FOXO1 in Tfh differentiation is supported by the known signaling pathway downstream of ICOS in T cells, that is, PI3K and AKT activation ([@bib41]), which was shown here to result in the inactivation of FOXO1. Finally, enforced nuclear expression of FOXO1 inhibits the differentiation Tfh cells, and the sum of these results provide a mechanism by which ITCH-mediated FOXO1 degradation is required for Tfh differentiation ([@bib52]).

These results demonstrate that inactivation of FOXO1 is an essential outcome of ICOS signaling in the contingency of CD4 T cell differentiation, and this establishes an important link in the signaling from ICOS to the induction of *Bcl6* expression. Previous studies have reported that FOXO1, FOXO3, or FOXO4 binds upstream of *BCL6* acting as a postive regulator in different types of cells ([@bib35; @bib31]), whereas we found that a *Foxo1* deletion enhances BCL6 expression. We also found, using ChIP-seq, that FOXO1 binding in naive CD4 T cells was restricted to a site at the beginning of the *Bcl6* first intron (also the case for naive and activated CD8 T cells---data not shown), and we propose that FOXO1 regulates *Bcl6* in T cells through transcriptional repression. Repression at this region is also associated with STAT5 competition for STAT3 binding ([@bib50]). In addition, this region of the first *BCL6* intron is often mutated in diffuse large B cell lymphomas (DLBCL) ([@bib27]). The mechanisms of *Bcl6* regulation in T cells are not as well studied, although there is evidence for contributions from STAT3, STAT5, and BATF ([@bib25]).

Combined with previous results showing that FOXO1 is required for Treg differentiation ([@bib22; @bib33]), a possibility is that the extent or duration of FOXO1 nuclear exclusion is one factor determining the fate of antigen-activated CD4 T cells. Whether the contingency decision is simply stochastic or depends upon an undetermined variable such as strength of signal (TCR peptide-MHC affinity or avidity), concentration of free cytokines, or location, is unknown. Nonetheless, the differential requirements for FOXO1 activity likely explain why Tfr cells derive from tTregs and not pTregs ([@bib7; @bib24]). Naive T cells could not simultaneously receive an ICOS signal and maintain FOXO1 activity---both of which would be required for Tfr differentiation from naive T cells ([@bib18; @bib42]). Rather, tTregs differentiate into stable Tregs in the thymus, and can thus receive an ICOS signal in peripheral lymphoid organs, which might allow them to inactivate FOXO1 and further differentiate into Tfr cells.

The mechanism by which FOXO1 affects Tfh differentiation appears to include its role in the regulation of *Icos* and *Bcl6*, but in addition, other transcription factors that have been implicated in Tfh differentiation. BATF is required for Tfh differentiation and appears to directly control *Bcl6* ([@bib2; @bib20]). Within a 35 kb region of the genome that includes only the *Batf* gene, there is a single and very strong FOXO1 peak (rank 411 of 4333), and this peak is located within 100 bp upstream of the *Batf* TSS ([Figure S5](#app2){ref-type="sec"}). Similarly, IRF4 is required for Tfh differentiation ([@bib3]), and a FOXO1 binding site was detected 1,200 bp upstream of the *Irf4* TSS, and three peaks were detected 37 kb, 43 kb, and 83 kb downstream (rank 1578, 359, 2050 of 4333). On the other hand, other genes important for Tfh differentiation such as *Id3* and *Ascl2* have no proximal FOXO1 binding sites ([@bib28; @bib26]). With the strong caveat that enhancers can be located up to 1 Mb away from the transcription start site ([@bib45]), the experiments suggest that FOXO1 plays a role in directly regulating a part of the program of gene expression important for Tfh differentiation.

Tfh cells are known to have altered expression of homing molecules that directly control their localization into the B cell follicles. In addition to increased CXCR5 expression, Tfh cells have been shown to have increased expression of CXCR4 but reduced expression of CCR7, CD62L, PSGL1 (encoded by *Selplg*), and EBI2 (encoded by *Gpr183*) ([@bib10; @bib16; @bib37; @bib23]). In accord, *Foxo1*^KO^ cells displayed increased expression of CXCR5 and CXCR4 in comparison with WT Tfh cells, but PSGL1 and CD62L expression was decreased day 4 post immunization. FOXO1 has also been shown to upregulate expression of CCR7 through its control of KLF2 expression. These results raise the possibility that loss of FOXO1 might increase Tfh differentiation by controlling expression of these homing molecules consistent with FOXO1 binding sites located proximal to *Cxcr5*, *Cxcr4*, *Ccr7*, *Selplg*, and *Gpr183*.

We propose that the presence or absence of FOXO1 in the landscape of promoters and enhancers found at early stages of T cell activation is a key step in determining the progression of differentiation that ultimately gives rise to one or more functional T helper cell subsets. An implication of this work is that endocrine signaling known to inactivate FOXO1 in liver, muscle, and fat might do so as well in T cells, and thus the immune response to an infectious agent might be skewed depending upon the physiological condition of the host.

Experimental Procedures {#sec4}
=======================

Mice {#sec4.1}
----

Mice were maintained in a specific-pathogen free vivarium. All experiments were carried out in accordance to the Institutional Animal Care and Use Committee of University of California, San Diego. *Foxo1*^f/f^, *Foxo1*^f/f^*Cd4Cre* (*Foxo1*^TKO^), *Foxo1*^f/f^*Cd4Cre* OTII, and *Foxo1*^f/f^*Rosa26*^Cre-ERT2^ (*Foxo1*^KO^) mice of mixed C57BL/6 and FVB genetic backgrounds have been previously described ([@bib22]). For other experiments, *Foxo1*^f/f^ mice were backcrossed to C57BL/6 (Jackson) for at least 13 generations and then crossed to *Rosa26*^Cre-ERT2^, which had also been backcrossed to C57BL/6 for 10 generations, and OTII to generate backcrossed *Foxo1*^f/f^*Rosa26*^Cre-ERT2^ and *Foxo1*^f/f^ *Rosa26*^Cre-ERT2^ OTII mice. For additional controls, OTII mice were crossed to CD45.1, or *Rosa26*^Cre-ERT2^ mice as indicated. *Rosa26-hFoxo1*^AAA^ *(Foxo1*^AAA^*)* ([@bib34]) were bred to OT-II mice. Unless otherwise indicated, CD45.1 mice were used as hosts for adoptive transfer experiments. CD45.1 mice were purchased from Jackson Laboratories and maintained in our colony. *Foxo1*^f/f^*Cd4Cre* mice were crossed to B6.129P2-ICOStm1Mak/J (*Icos*^−/−^) mice from Jackson Laboratories. *Icosl*^−/−^ host mice were purchased from Jackson Laboratories and maintained at La Jolla Institute for Allergy and Immunology. Bone-marrow chimera experiments were carried out at the University of Washington. The FOXO1-EGFP knock-in mice were generated at Taconic as described in [Supplemental Information](#app2){ref-type="sec"}.

Adoptive Transfer Experiments {#sec4.2}
-----------------------------

For in vivo Tfh cell experiments in which mice were immunized, OTII cells were enriched by negative magnetic selection for naive CD4 (CD69^−^CD25^−^CD4^+^) cells and 0.1 to 0.5 × 10^6^ OTII cells were adoptively transferred into CD45.1 hosts unless other indicated. Approximately 2 to 12 hr later, mice were immunized intraperitoneally (i.p.) with 0.1 mg of OVA in 200 μl of Sigma Adjuvant System (Sigma) as per manufacturer's instructions. The phenotype of transferred splenocytes at indicated days post immunization was determined. For experiments plus or minus inhibitory ICOSL-specific antibody (Clone: HK5.3, BioXCell) 100 μg of anti-ICOSL or isotype control were injected intravenously (i.v.) and an additional 100 μg were injected i.p. immediately prior to immunizations. An additional 100 μg of the appropriate antibody was injected i.p. 2 dpi. Where indicated, mice were infected with 10 × 10^6^ cfu of ΔActA-Lm-OVA i.v.

For VSV-OVA co-transfer experiments, 10,000 cells of each WT OTII (CD45.1.2) and *Foxo1*^KO^ OTII (CD45.2) cells were transferred into the same host mice and the next day mice were infected with 10^5^ pfu of VSV-OVA. Phenotype of transferred cells was determined 6--7 days post infection by flow cytometry.

In Vitro ICOS Signaling Experiments {#sec4.3}
-----------------------------------

To study ICOS signaling, we activated and restimulated cells with anti-ICOS similarly to previously described ICOS restimulation conditions ([@bib40]). Briefly, WT or FOXO1-GFP naive CD4 (CD69^−^CD25^−^CD4^+^) T cells were purified by negative depletion and activated with anti-CD3 (2C11), 1 μg/ml anti-CD28 plus or minus 10 μg/ml anti-IFN-γ, 10 μg/ml anti-IL-4, 50 ng/ml IL-6, and 10 ng/ml IL-21 (iTfh conditions) in RP10 for 48 hr. After 48 hr, the cells were rested in RP10 for 24 hr. Following the rest, the cells were restimulated with soluble anti-CD3 0.5 μg/ml, goat anti-hamster 20 μg/ml (Vector Labs, Burlingame, CA) with or without stimulatory 2 μg/ml anti-ICOS (Clone: C398.4A, eBioscience). To determine whether ICOS signaling inactivated, we collected FOXO1 cells at 30 m or 24 hr post restimulation and analyzed FOXO1-GFP compared to DRAQ5 staining using AMNIS ImageStream and BD LSR Fortessa analysis. To determine whether ICOS signaling through FOXO1 might be involved in ICOS upregulation of BCL6, we left WT or *Foxo1*^KO^ CD4 T cells in culture for 24 hr post restimulation and analyzed expression of Tfh markers by flow cytometry.

Imaging Flow Cytometry {#sec4.4}
----------------------

FOXO1-GFP localization was determined using the 60× objective on ImageStreamX MkII (Amnis/EMD Millipore). FOXO1-GFP signal was compared to the nuclear mask generated using signal from DRAQ5 (Cell Signaling). Data was analyzed with IDEAS software including the nuclear localization wizard. To determine percent of cells with cytoplasmic FOXO1-GFP, we gated cells with a similarity score from FOXO1-GFP and DRAQ5 less than the similarity score that was determined by visual examination of images to represent cells is which FOXO1-GFP was excluded from the nucleus. The nuclear intensity of FOXO1-GFP reflects the amount of FOXO1-GFP within the DRAQ5 nuclear mask.

Generation, Infection, and Analysis of Mixed Bone-Marrow Chimeras {#sec4.5}
-----------------------------------------------------------------

Bone-marrow cells were harvested from femurs, tibias, and humeri. T cells were depleted from bone-marrow cell suspensions with anti-Thy1.2 (30-H12, eBioscience) and low-toxicity rabbit complement (Cedarlane Laboratories). CD45.1^+^ wild-type bone-marrow cells were mixed with 4-fold excess CD45.2^+^ Foxo1TKO bone-marrow cells. 5--10^6^ total bone-marrow cells were injected into lethally irradiated (10 Gy) CD45.1.2^+^ hosts. Eight weeks later, chimerism was assessed by flow cytometry and mice were injected intravenously with 10^7^ actA deficient *Listeria monocytogenes* (Lm) bacteria engineered to secrete a fusion protein containing an immunogenic peptide (Lm-2W) ([@bib9]). Nine days later, mice were sacrificed, spleen and lymph node cells were harvested, and lymphocytes were stained for 1 hr at room temperature with LLOp:I-A^b^-streptavidin-allophycocyanin tetramers and 2 mg of phycoerythrin-conjugated antibody specific for CXCR5 (2G8; Becton Dickinson). Samples were then enriched for bead-bound cells on magnetized columns ([@bib29]). Cells were then analyzed by flow cytometry.

Statistical Analyses {#sec4.6}
--------------------

Unless otherwise indicated two-tailed, unpaired Student t tests were used to determine statistical significance. ^∗^ p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.

Supplemental Information {#app2}
========================

Document S1. Figures S1--S5 and Supplemental Experimental ProceduresDocument S2. Article plus Supplemental Information
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![Loss of FOXO1 Amplifies Tfh Differentiation\
(A and B) WT or *Foxo1*^TKO^ OTII cells were transferred into CD45.1 hosts, immunized with OVA plus adjuvant, and spleen cells were analyzed days 4 post immunization. (A) The percentages of CXCR5^lo^, CXCR5^int^, and CXCR5^hi^BCL6^+^ cells (left) or PD1 expression (right) were determined by flow cytometry and (B) The numbers of each cell type in the spleen were calculated, representative of two independent experiments.\
(C) Adoptive transfer similar to (A) above were carried out with *Foxo1*^KO^ OTII cells and the percentages of WT or *Foxo1*^KO^ CXCR5^lo^, CXCR5^int^, and CXCR5^hi^BCL6^+^ cells were determined days 4 post immunization.\
(D) Expression of CXCR5, BCL6, and PD1 from WT (filled histogram) or *Foxo1*^KO^ (open histogram) CXCR5^int^ OTII cells days 4 post immunization (n = 3). Representative of two independent experiments.\
(E) Analysis of CXCR5 versus BCL6 expression of WT *Foxo1*^KO^ cells 4 days post infection with ΔActA-Lm expressing OVA (Left). Plots show CXCR5, BCL6, or PD1 MFI (Right). p \< 0.01 for all three parameters. Data is representative of two individual experiments.\
(F) Expression of CCR7, CD62L, and PSGL1 on WT or *Foxo1*^KO^ OTII cells days 4 post immunization is shown (n = 3--4). Data are representative from at least two individual experiments.](gr1){#fig1}

![The Regulation FOXO1 and ICOS Is Coupled via a Negative Feedback Loop\
(A) Plots show MFI of FOXO1-GFP (left), similarity score between DRAQ5 and FOXO1-GFP (Middle), and the percent of cells with FOXO1-GFP exclusively in the cytoplasm (right) 30 min post restimulation through CD3 and ICOS. None indicates the cells were not restimulated. Data are representative of two independent experiments.\
(B) Plots show MFI of total FOXO1-GFP (left), similarity score between DRAQ5 and FOXO1-GFP (middle), and intensity of FOXO1-GFP overlapping with the nuclear mask (right) 24 hr post restimulation.\
(C) ICOS expression on WT or *Foxo1*^KO^ CD4 cells activated in vitro for 72 hr via CD3 and CD28 in the presence or absence of iTfh conditions. The histograms show the expression of ICOS on cells activated with anti-CD3 and anti-CD28 without the addition of exogenous cytokines (left). Data are representative of two independent experiments.\
(D) Histograms depict ICOS expression on CXCR5^lo^, CXCR5^int^, or CXCR5^hi^BCL6^+^ from WT or *Foxo1*^KO^ OTII cells days 4 post immunization. Data are representative of two independent experiments.\
(E) Analysis of FOXO1-specific ChIP-Seq of naive CD4 T cells. The most frequent consensus binding site was determined to be TGTTTAC, the size of the nucleotide in the graphic corresponds with its frequency.\
(F) The *Icos* locus is shown for FOXO1-specific ChIP-seq (top track) (see also [Figure S2](#app2){ref-type="sec"}B), and the centrally positioned nucleotide sequence within the promoter peak is listed. The bottom track shows mammalian sequence conservation (UCSC Genome Browser).\
(G) FOXO1-specific ChIP of *Icos* locus from WT CD4 T cells activated in vitro.](gr2){#fig2}

![Tfh Differentiation in the Absence of FOXO1 Is Independent of ICOSL\
(A and B) WT or *Foxo1*^KO^ OTII cells were transferred into CD45.1 hosts and mice were immunized with OVA plus adjuvant. Where indicated, mice were treated with blocking anti-ICOSL. (A) The percentages of CXCR5^lo^, CXCR5^int^, and CXCR5^hi^BCL6^+^ cells and (B) total number of CXCR5^+^ (including both the CXCR5^int^ and CXCR5^hi^ populations) of WT or *Foxo1*^KO^ OTII cells is shown. One of four representative experiments.\
(C) The percentages of CXCR5^lo^, CXCR5^int^, and CXCR5^hi^BCL6^+^ cells of WT or *Foxo1*^KO^ OTII cells in WT or *Icosl*^−/−^ hosts days 4 post immunization. Data are representative of two independent experiments.\
(D) Numbers of WT or *Foxo1*^KO^ CXCR5^+^ (including both the CXCR5^int^ and CXCR5^hi^ populations) OTII cells days 4 post immunization from WT or *Icosl*^−/−^ hosts plotted on a log scale. Data are pooled from two independent experiments.](gr3){#fig3}

![Loss of FOXO1 Promotes B Cell Help and Antibodies in the Absence of ICOS\
(A) The percentage of LN CD4^+^CD44^hi^ cells expressing CXCR5 and PD1 is shown from WT; *Foxo1*^TKO^; *Icos*^−/−^; and DKO. Data are representative of four independent experiments.\
(B and C) The percentages of isotype switched (IgM^−^IgD^−^) (B) and GC (GL7^+^CD95^+^) (C) B cells present are shown. Comparing WT and *Foxo1*^TKO^ or *Icos*^−/−^ and DKO p \< 0.01. Data are representative of four independent experiments.\
(D) Plot shows relative amounts of IgG anti-dsDNA in sera. Data are representative of three independent experiments (left). The levels of total IgG in sera are plotted. Data shown are pooled from two experiments (right).\
(E) Plots show the percentage of CXCR5^+^ T~FR~ cells within LN Treg (CD4^+^FOXP3^+^) population for each genotype. Data shown are from one of two independent experiments.](gr4){#fig4}

![FOXO1 Negatively Regulates BCL6 Expression\
(A and B) WT or *Foxo1*^KO^ naive CD4 cells activated under iTfh conditions, rested, and then restimulated via CD3 with or without antibody specific for ICOS. (A) BCL6 levels determined by flow cytometry. None indicates the cells were not restimulated, and the MFI is shown for one example. The filled (WT) and open (*Foxo1*^KO^) gray circles on the graph represent background staining of a control antibody for each individual biological replicate. Data are representative of three independent experiments. (B) *Bcl6* levels were determine by qPCR. Data shown are from one of two experiments.\
(C) WT (CD45.1) and *Foxo1*^KO^ (CD45.2) cells were co-cultured under conditions as in (A) and the MFI of WT and *Foxo1*^KO^ cells from each well are shown. Gray circles represent background staining of a control antibody. Data are representative of two individual experiments.\
(D) The *Bcl6* locus is shown for FOXO1-specific ChIP-Seq (top track) (see also [Figure S4](#app2){ref-type="sec"}B), and the centrally positioned nucleotide sequences within the peak found in the first intron are listed. The bottom track represents mammalian sequence conservation.\
(E and F) FOXO1-specific ChIP of *Bcl6* locus from (E) naive CD4 T cells or (F) CD4 T cells activated as in (A) and restimulated with CD3- and ICOS-specific antibodies as in (A) for 1 hr or 24 hr. Filled bars represent percent of input of anti-FOXO1 immunoprecipitation. Open bars represent percent of input of the IgG control. None indicates the cells were activated and rested but not restimulated. Data are representative of two independent experiments.](gr5){#fig5}

![Enforced Nuclear Localization of FOXO1 Suppresses Tfh Differentiation\
(A) ICOS expression or (B) the percentages of CXCR5^lo^, CXCR5^int^, and CXCR5^hi^PD1^+^ cells from WT or *Foxo1*^AAA^ OTII cells day 4 post immunization. In each case, p \< 0.001. Data are representative of two independent experiments.](gr6){#fig6}

![FOXO1 KO T Cells Have Reduced Ability to Differentiate into GC-Tfh Cells\
(A) Mixed bone-marrow chimeras (WT-CD45.1 and *Foxo1*^TKO^) were infected with ΔActA-Lm. CD4^+^B220^-^CD44^hi^LLO^+^ cells were phenotyped from each donor. Representative of two separate experiments.\
(B) MAF expression within CXCR5^lo^, CXCR5^int^, or CXCR5^hi^PD1^hi^ OTII T cells day 4 post immunization (n = 3). Representative of three independent experiments.\
(C) Percentages of CXCR5^lo^, CXCR5^int^, and CXCR5^hi^MAF^hi^ subsets within CD4^+^ WT OTII T cells day 4 post immunization in the presence or absence of blocking anti-ICOSL. Representative of four host mice per condition.\
(D) Analysis similar to (C) using WT or *Foxo1*^KO^ OTII cells assayed at day 4 (n = 3--5) and day 7 (n = 3). One of at least two representative experiments.\
(E) Plots show CXCR5 versus BCL6 (left) or CXCR5 versus PD1 (right) at day 7 post immunization. One of two representative experiments.\
(F) Expression of FOXO1 in CXCR5^lo^, CXCR5^int^, and CXCR5^hi^BCL6^+^ subsets of WT OTII cells at day 4 and day 7 post immunization.\
(G) The proportions of CXCR5^lo^, CXCR5^int^, or CXCR5^hi^MAF^+^ cells at day 6 post VSV-OVA infection from co-transferred WT and *Foxo1*^KO^ OTII T cells. Data are representative of two independent experiments.\
(H) Plots show CXCR5 versus BCL6 (left) or CXCR5 versus PD1 (right) expression from cotransferred WT or *Foxo1*^KO^ OTII T cells at day 6 post VSV-OVA infection (as in G). Data are representative of two independent experiments.](gr7){#fig7}
